Breakthrough Cancer Vaccine Shows 90% Efficacy in Phase 2 Trials at Tata Memorial

Tata Memorial Hospital, Mumbai, has announced remarkable Phase 2 trial results for a personalized mRNA cancer vaccine developed in collaboration with German biotech firm BioNTech. The vaccine, customized for each patient's tumor profile, showed a 90% reduction in cancer recurrence rates in head and neck cancer patients over an 18-month follow-up period.

How the Vaccine Works

The vaccine works by training the patient's immune system to recognize and attack specific proteins (neoantigens) found only on their cancer cells. After surgical removal of the tumor, a biopsy sample is sent to a specialized lab where AI algorithms identify the most immunogenic neoantigens. A custom mRNA vaccine encoding up to 20 neoantigens is then manufactured and administered within four weeks.

In the trial, 120 patients received the personalized vaccine along with standard immunotherapy, while 60 received immunotherapy alone. The vaccine group showed a dramatically lower recurrence rate of 8% compared to 47% in the control group. Overall survival data is still maturing but trends strongly in favor of the vaccine arm.

"We are witnessing the beginning of a new era in oncology. Personalized cancer vaccines could transform cancer from a death sentence to a manageable condition for millions of patients," said Dr. Rajendra Badwe, Director of Tata Memorial Hospital.

The cost of manufacturing each personalized vaccine is currently around Rs 15 lakh, but Tata Memorial is working with Indian pharmaceutical companies to reduce this to under Rs 3 lakh using domestic manufacturing capabilities. A Phase 3 trial across 15 cancer centres in India is planned for late 2026. The government has indicated willingness to include the vaccine in its Ayushman Bharat coverage if Phase 3 results are confirmatory.